NYMC Faculty Publications

Tolerability and Safety Outcomes of First-Line Oral Second-Generation Antipsychotics in Patients With Schizophrenia

Author Type(s)

Faculty

DOI

10.1080/14740338.2024.2328812

Journal Title

Expert Opinion on Drug Safety

First Page

399

Last Page

409

Document Type

Article

Publication Date

4-1-2024

Department

Psychiatry and Behavioral Sciences

Abstract

INTRODUCTION: Antipsychotics are the foundation of pharmacologic treatment for schizophrenia. There are many oral antipsychotics available and given that these medications are generally considered comparably efficacious when titrated to an adequate dose, their varied tolerability, and safety profiles become critically important for medication selection. AREAS COVERED: This paper reviews tolerability and safety considerations for first-line second-generation oral antipsychotics currently approved for the treatment of schizophrenia in the USA. Excluded from consideration are clozapine and non-oral formulations. EXPERT OPINION: Among antipsychotics, there are many differences in adverse reactions observed in clinical trials, such as variable likelihood to cause sedation vs insomnia, weight gain and abnormalities in glucose/lipid metabolism, hyperprolactinemia, potential for impact on the QT interval, and motoric adverse effects. Additional safety data that can help with medication selection include safety in pregnancy and lactation, and potential for drug-drug interactions. Ultimately, working with patients to personalize treatment by focusing on safety and individual tolerability considerations for various adverse effects can help in building a therapeutic alliance and improving patients' outcomes.

Link to Full Text

Share

COinS